Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR | Market Cap | 81.55B |
| Revenue (ttm) | 26.52B |
| Net Income (ttm) | 3.50B |
| Shares Out | 453.16M |
| EPS (ttm) | 7.74 |
| PE Ratio | 23.25 |
| Forward PE | 18.63 |
| Dividend | 0.80 (0.44%) |
| Ex-Dividend Date | Aug 1, 2025 |
| Volume | 681,593 |
| Average Volume | 2,273,382 |
| Open | 181.60 |
| Previous Close | 181.12 |
| Day's Range | 179.50 - 181.97 |
| 52-Week Range | 171.00 - 358.70 |
| Beta | 1.26 |
| RSI | 21.09 |
| Earnings Date | Aug 11, 2025 |
About Marksans Pharma
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, an... [Read more]
Financial Performance
In 2024, Marksans Pharma's revenue was 26.23 billion, an increase of 20.46% compared to the previous year's 21.77 billion. Earnings were 3.81 billion, an increase of 21.32%.
Financial StatementsNews
Marksans Pharma’s UK subsidiary Relonchem secures marketing authorization from MHRA for Metformin tablets
Marksans Pharma Limited (NSE: MARKSANS, BSE: 524404) announced that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare p...
Marksans Pharma shares drop 13% as Q1 net profit falls 34.3% YoY to Rs 58.3 crore, revenue down 5% YoY
Marksans Pharma’s shares tumbled 13% in today’s trade after the company posted a disappointing set of numbers for the first quarter of FY26. The stock, which opened at ₹211.15 against the previous clo...
Marksans Pharma subsidiary gets USFDA final approval for 20 mg Omeprazole Delayed-Release Tablets
Marksans Pharma Limited has announced the final approval of the company’s wholly owned subsidiary, Marksans Pharma Inc., for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release ...
Marksans Pharma receives EIR from USFDA for Time-Cap Labs facility
Marksans Pharma has announced a positive update regarding its US operations. The company shared that its wholly owned subsidiary, Time-Cap Laboratories Inc., based in Farmingdale, New York, has succes...
Marksans Pharma’s UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the...
Marksans Pharma shares jump 3% after large block deal worth Rs 257 crore
Shares of Marksans Pharma Ltd climbed 2.92% to ₹257.25 in early trade on Wednesday, June 11, following a significant block deal executed in Tuesday’s session. According to exchange data, around 1.02 c...
Marksans Pharma Block Deal: Over 1 crore shares worth Rs 257 crore change hands at Rs 249.95 per share
Shares of Marksans Pharma Ltd. will be in focus on Wednesday, June 11, after a significant block deal took place during Tuesday’s trading session. As per exchange data, 1,02,73,443 shares of the compa...
Marksans Pharma’s subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA...
Marksans Pharma’s UK arm gets marketing approval for Sennosides 7.5 mg tablets
Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets f...
Marksans Pharma’s UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution
Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency...
Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility
Marksans Pharma Limited has announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facilit...
Marksans Pharma shares up nearly 4% as company secures Australian TGA approval for Goa facility
Shares of Marksans Pharma Limited surged nearly 4% after the company announced that its manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has received approval from t...
Marksans Pharma’s Goa facility gets Australian TGA approval for Solid Dosage manufacturing
Marksans Pharma Limited has received approval from the Australian Therapeutic Goods Administration (TGA) for its state-of-the-art manufacturing facility in Verna, Goa. This approval allows the company...
Marksans Pharma’s subsidiary Relonchem receives marketing authorization from UK MHRA for Baclofen 10 mg tablets
Marksans Pharma Limited has achieved a key milestone as its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Ag...
Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets
Marksans Pharma Limited has announced that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets in the U...
Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg
Marksans Pharma Limited saw a 2% surge in its stock price after receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine...
Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg
Marksans Pharma Limited has announced receiving final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. This...
Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ...
Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansion
Marksans Pharma shares jump over 3% on Q2 results
Marksans Pharma Ltd. has announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024, reflecting strong growth in both revenue and prof...
Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY
Marksans Pharma Ltd. reported unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024. Q2 FY25 financial analysis for Marksans Pharma with figure...
Marksans Pharma Q2 FY25 results: Stock surge over 3% ahead of result announcement
Marksans Pharma’s stock saw a significant uptick, jumping over 3% ahead of its Q2 FY25 results. The stock opened at ₹290.70, reaching a high of ₹299.20, and closing near its low of ₹290.65. With a 52-...